

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Bush *et al.*

Appl. No. 09/956,980

Filed: September 21, 2001

For: **Agents for Use in the Treatment
of Alzheimer's Disease**

Confirmation No. 6687

Art Unit: 1614

Examiner: Weddington, K.

Atty. Docket: 0609.4550001/JAG/FRC

Second Supplemental Information Disclosure Statement

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

RECEIVED
NOV 19 2003
TECH CENTER 1600/2900

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Second Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' First Supplemental Information Disclosure Statement filed on May 2, 2003, in connection with the above-captioned application. A copy of each document is also provided.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.


This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection, or Notice of Allowance, or an action that otherwise closes prosecution in the application. Attached is our PTO-2038 Credit Card Payment Form in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Frank R. Cottingham
Attorney for Applicants
Registration No. 50,437

Date: Nov. 10, 2003
1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600



FORM PTO-1449

SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
0609.455001/JAG/FRCAPPLICATION NO.
09/956,980APPLICANT
Bush et al.FILING DATE
September 21, 2001GROUP
1614

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
|---------------------|-----|-----------------|------------|-------------|-------|-----------|-------------|
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH2 | 6,323,218 B1 | 11/27/2001 | Bush et al. | | | 03/11/1998 |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
|---------------------|----|-----------------|------|---------|-------|-----------|-------------|
| | AL | | | | | | Yes No |
| | AM | | | | | | Yes No |
| | AN | | | | | | Yes No |
| | AO | | | | | | Yes No |
| | AP | | | | | | Yes No |


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

| | | | |
|--|----|-----------|---|
| | AR | <u>68</u> | Cherny, R.A., et al., "Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β -Amyloid Accumulation in Alzheimer's Disease Transgenic Mice," <i>Neuron</i> 30:665-676, Cell Press (2001) |
| | AS | <u>68</u> | Cherny, R.A., et al., "Chelation and Intercalation: Complementary Properties in a Compound for the Treatment of Alzheimer's Disease," <i>J. Struct. Bio.</i> 130:209-216, Academic Press (2000) |
| | AT | <u>68</u> | Kisilevsky, R., and Fraser, P.E., "A β Amyloidogenesis: Unique, or Variation on a Systemic Theme?" <i>Crit. Rev. Biochem. Mol. Biol.</i> 32:361-404, CRC Press LLC (1997) |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



| | | |
|--|---|-------------------------------|
| FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT | ATTY. DOCKET NO. 0609.455001/JAG/FRC | APPLICATION NO. 09/956,980 |
| | APPLICANT Bush et al. | |
| | FILING DATE September 21, 2001 | GROUP 1614 |

| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|----|-----------------|------|------|-------|-----------|-------------|
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|----|-----------------|------|---------|-------|-----------|-------------|
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
| | AL | | | | | | Yes No |
| | AM | | | | | | Yes No |
| | AN | | | | | | Yes No |
| | AO | | | | | | Yes No |
| | AP | | | | | | Yes No |

| OTHER (Including Author, Title, Date, Pertinent Pages, etc.) | | | |
|--|----|-----------|--|
| | AR | <u>69</u> | Maury, C.P.J., "Molecular Pathogenesis of β -Amyloidosis in Alzheimer's Disease And Other Cerebral Amyloidoses," <i>Lab. Invest.</i> 72:4-16, The United States and Canadian Academy of Pathology, Inc. (1995) |
| | AS | <u>69</u> | Gnjec, A., et al., "Transition Metal Chelator Therapy-A Potential Treatment for Alzheimer's Disease?" <i>Front. Biosci.</i> 7:d1016-1023, Frontiers in Bioscience Publications (2002) |
| | AT | <u>69</u> | Fonte, J., et al., "The severity of cortical Alzheimer's type changes is positively correlated with increased amyloid- β Levels: Resolubization of amyloid- β with transition metal ion chelators," <i>J. Alzheimer's Dis.</i> 3:209-219, IOS Press (2001) |

| | |
|----------|-----------------|
| EXAMINER | DATE CONSIDERED |
|----------|-----------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



| | | |
|--|---|-------------------------------|
| FORM PTO-1449 <u>SECOND SUPPLEMENTAL</u> <u>INFORMATION DISCLOSURE STATEMENT</u> | ATTY. DOCKET NO. 0609.455001/JAG/FRC | APPLICATION NO. 09/956,980 |
| | APPLICANT Bush et al. | |
| | FILING DATE September 21, 2001 | GROUP 1614 |

| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|----|-----------------|------|------|-------|-----------|-------------|
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |

RECEIVED

NOV 19 2003

TECH CENTER 1600/2900

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|----|-----------------|------|---------|-------|-----------|-------------|
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
| | AL | | | | | | Yes No |
| | AM | | | | | | Yes No |
| | AN | | | | | | Yes No |
| | AO | | | | | | Yes No |
| | AP | | | | | | Yes No |

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

| | | | |
|--|----|----|--|
| | AR | 70 | Gillmore, J.D., et al., "Amyloidosis: A Review of Recent Diagnostic and Therapeutic Developments," <i>Br. J. Haematol.</i> 99:245-256, Blackwell Science Ltd. (1997) |
| | AS | 70 | Schnabel, J., "New Alzheimer's Therapy Suggested," <i>Science</i> 260:1719-1720, The American Association for the Advancement of Science (1993) |
| | AT | 70 | "Bathocuprione," <i>Biochemicals, Organic Compounds, Diagnostic Reagents</i> , pg. 149, catalog #B1000, Sigma Chemical Co. (1995) |

| | |
|----------|-----------------|
| EXAMINER | DATE CONSIDERED |
|----------|-----------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
0609.455001/JAG/FRCAPPLICATION NO.
09/956,980APPLICANT
Bush et al.FILING DATE
September 21, 2001GROUP
1614

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
|---------------------|----|-----------------|------|------|-------|-----------|-------------|
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
|---------------------|----|-----------------|------|---------|-------|-----------|-------------|
| | AL | | | | | | Yes No |
| | AM | | | | | | Yes No |
| | AN | | | | | | Yes No |
| | AO | | | | | | Yes No |
| | AP | | | | | | Yes No |

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

| | | | |
|--|----|-----------|--|
| | AR | <u>71</u> | Goodman, L.S., and Gilman, A., "Drug Absorption, Bioavailability, and Routes of Administration," in Goodman and Gilman's The Pharmacological Basis of Therapeutics, Eighth Edition, McGraw-Hill, Inc., New York, NY, pp.5-6 (1993) |
| | AS | | |
| | AT | | |

RECEIVED
NOV 19 2003
TECH CENTER 1600/2900

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.